Staceyann Rookwood
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 9.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,011 and has fallen 84.9% since, to $304 in 2025. Among family clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $35.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$398
- EMD Serono, Inc.$395
- Johnson & Johnson$393
- Seagen Inc.$340
- E.r. Squibb & Sons, L.L.C.$278
- Novartis$264
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,09493%
- Education$2997%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $398 |
| EMD Serono, Inc. | 3 | $395 |
| Johnson & Johnson | 13 | $393 |
| Seagen Inc. | 5 | $340 |
| E.r. Squibb & Sons, L.L.C. | 4 | $278 |
| Novartis | 16 | $264 |
| Karyopharm Therapeutics Inc. | 2 | $244 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $189 |
| Daiichi Sankyo Inc. | 3 | $152 |
| Sobi, Inc | 7 | $148 |
| Gilead | 2 | $145 |
| Jazz Pharmaceuticals Inc. | 1 | $130 |
| Mirati Therapeutics, Inc. | 1 | $123 |
| Puma Biotechnology, Inc. | 6 | $123 |
| Eisai Inc. | 1 | $123 |
| Sanofi | 6 | $109 |
| Blue Earth Diagnostics | 4 | $85 |
| AstraZeneca | 5 | $84 |
| Bristol Myers Squibb | 4 | $75 |
| Boehringer Ingelheim | 3 | $62 |
| Lilly USA, LLC | 3 | $61 |
| Amgen | 3 | $60 |
| AVEO Pharmaceuticals, Inc. | 2 | $42 |
| Acrotech Biopharma Inc. | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $32 |
| Myovant Sciences Inc. | 2 | $30 |
| Taiho Oncology, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Pfizer | 1 | $25 |
| Morphosys, US Inc. | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Beigene USA, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| GSK | 1 | $18 |
| Epizyme, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,393 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 35 | $6,723 |
| Letrozole | 113 | $1,858 |
| Anastrozole | 52 | $1,010 |
| Raloxifene Hcl | 17 | $578 |
| Hydroxyurea | 18 | $260 |
| Tamoxifen Citrate | 11 | $113 |
| Omeprazole | 11 | $108 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 29 | $60 |
Paid to pharmacies, not to this prescriber.
Other family in Bronx
- Vladimir ByhovskyBronx$70K
- May YuBronx$24K
- Daphenie FauvelBronx$21K
- Schevaughn Carr CelestineBronx$20K
- Nighat SaeedBronx$19K
- Keisha BallentineBronx$18K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.